Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | BAX | Q07812 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410748 | 0.97 | DNM1 (0.69) | DNM1MAPTSMN1; SMN2RAD52NLRP1 | |
| SCHEMBL408405 | 0.95 | DNM1 (0.77) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL410692 | 0.92 | DNM1 (0.85) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL28594492 | 0.90 | DNM1 (0.60) | DNM1MAPTSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL18721925 | 0.85 | DNM1 (0.77) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL410581 | 0.85 | DNM1 (0.77) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL407111 | 0.85 | DNM1 (0.55) | DNM1MAPTSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL29351340 | 0.85 | DNM1 (1.00) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL29391692 | 0.85 | DNM1 (1.00) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL410011 | 0.85 | DNM1 (0.72) | DNM1MAPTSMN1; SMN2NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | disclosed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | DNM1 638/4885MAPT 142/4885SMN1; SMN2 63/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | DNM1 638/4885MAPT 142/4885SMN1; SMN2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.